Aptuit to buy Quintiles units in $125M deal

Aptuit has struck a deal to acquire three Quintiles Transnational business units for $125 million, the two companies announced. The units, which now employ 1,400 and provide services to 19 of the world's 20 largest drug companies, are key to Aptuit's strategy of building a comprehensive drug-development services company. Aptuit intends to reorganize the units and to invest $50 million in developing them over the next several years but says the transition will be "virtually seamless" to employees and customers. The deal also includes a multi-year joint-marketing deal between the two companies.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.